DR AL KOLB Drives Chip-Man Technologies Expansion into USA Market
News Nov 16, 2006
Chip-Man Technologies Ltd. has announced that Dr Al Kolb, KeyTech Solutions, has been contracted as a consultant to assist in the introduction of the Cell-IQ® to the United States (US).
He will also begin building a US base of operations. Dr Kolb, a well known and successful consultant on early drug discovery technologies, believes that Chip-Man and their Cell-IQ system will be very successful in the US. He said, “I have the opportunity to look at many companies and to evaluate new technologies. In my experience, Chip-Man and Cell-IQ both stand out”.
He continued, “The management team of Chip-Man are knowledgeable and experienced with a good understanding of the market and their customers. The Cell-IQ is an excellent and unique product that meets a real market need. We are looking forward to a successful launch of Cell-IQ in the US and establishing Chip-Man as a premier cell imaging and analysis company."
Dr Al Kolb operates his own consulting company, KeyTech Solutions, which focuses on the identification, development and commercialization of drug discovery technologies. He is one of the founders of The Society for Biomolecular Sciences and currently serves as its President.
He has worked for industry leaders such as Beckman and Packard (now PerkinElmer), and some of his projects have included the development of microplates and readers, assay technologies, as well as large scale automation systems.
He also serves as a scientific advisor to corporations, in addition to working with universities and a variety of companies in the evaluation of drug discovery technologies.
“Al is an excellent addition to our team” Chip-Man Technologies’ Chief Executive Officer Juha Korpinen explained. “His wealth of knowledge and understanding of the life science industry will help drive the CELL-IQ® into the US market.”
Cell-IQ represents a major breakthrough in cell analysis by enabling real time monitoring of all morphological and physiological changes in cell lines, primary cells, co-cultures and monolayer tissue models.
The Cell-IQ software “learns” to recognize and record cellular change and to output these results as real time moving images and simple multi-parameter graphics.
A research team developed a microfluidic-based drug screening chip that identifies synergistic interactions between two antibiotics in eight hours. This chip can be a cell-based drug screening platform for exploring critical pharmacological patterns of antibiotic interactions, along with potential applications in screening other cell-type agents and guidance for clinical therapies.READ MORE